Professor Glenda Halliday is one of the world’s leading neuroscientists has been recognised for her foundational work on neurodegenerative diseases. Professor Halliday’s research looks at how the human brain is affected structurally and biochemically by neurodegenerative diseases. Her curren...
Visit PageThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the 2021 Robert A. Pritzker Prize for Leadership in Parkinson’s Research award to Glenda Margaret Halliday, PhD, Australian National Health and Medical Research Council Leadership Fellow from the University of Sydney. The ...
Visit PageThe Australian Academy of Science has today recognised 22 of Australia’s most distinguished scientists, naming the 2021 Fellows of the Australian Academy of Science. Among this group is Professor Glenda Halliday who is acclaimed internationally for her research on neurodegeneration, making major i...
Visit PageToday we share the research of Professor Glenda Halliday and Dr Nicholas Dzamko and the world leading LKK2 research they are conducting at The University of Sydney. Funding of this research has been made possible by the generous support of individuals, families and businesses right across the countr...
Visit PageOn Saturday, February 11th, we celebrate the International Day of Women and Girls in Science, which was established by the United Nations General Assembly to promote full and equal access to and participation in science for women and girls. Did you know that in Australia, women make up just 13 perce...
Visit PageThere is very little data on the role of astrocytes in Parkinson’s disease. Additionally, astrocytes are notoriously regionally heterogeneous, so analysis of astrocyte expression profiles in non-PD affected brain regions may not be relevant. Dr. Halliday proposes to use digital-spatial profiling o...
Visit PageOur heroes this week are our fearless fundraisers running the Blackmores Sydney Running Festival this weekend! They’ve been training for months now and dedicating themselves to fundraising.
Visit PageShake It Up are excited to announce three new research projects which have been funded in collaboration with The Michael J. Fox Foundation. These studies will be conducted at The Brain and Mind Centre, Sydney University and The University of Queensland. The first of these studies extends biom...
Visit PageThis project will leverage digital spatial profiling technology to examine multiple molecular targets on immune-oncology pathways at different pathological progression stages of PD (Braak stages) using patient post-mortem tissue. If successful, this effort has the potential of identifying novel mole...
Visit Page“Forbes” recently published a story detailing a “milestone moment” in the history of LRRK2 and the linchpin role of The Michael J. Fox Foundation (MJFF) in ushering this promising genetic target forward. The LRRK2 gene was discovered in 2004, leucine-rich repeat kinase 2 (LRR...
Visit PageA dysfunction of the glucocerebrosidase (GCase) protein increases the risk of Parkinson’s disease (PD). Blood cells called monocytes produce large amounts of this protein. The aim of this study is to determine how well the GCase protein functions in monocytes from the blood of people diagnosed wit...
Visit PageI) Assess the presence of aggregated alpha-synuclein in inclusions and as diffuse oligomers in PD (Braak stage 4 and 6) and MSA (MSA-p and MSA-C) post-mortem tissues by IHC and IF using multiple antibodies selected for alpha-synuclien including MJF-14 2) Assess the presence of aggregated alpha-synuc...
Visit PageThis week we feature Dr Nicolas Dzamko. Based at The University of Sydney he is currently working alongside Professor Glenda Halliday on several exciting Parkinson’s research projects. Briefly outline where you commenced your research journey and where you are currently based I graduated with a bi...
Visit PageThe contribution of inflammation to Parkinson’s disease (PD) is increasingly being recognised. However, the stage of the disease in which inflammation is prevalent and/or important remains unclear. Our recent work suggests that inflammation may be increased early in the course of PD.
Visit PageIn the brains of people with Parkinson’s disease, the GBA protein appears to no longer fully function. Thus, therapies aimed at stabilizing glucocerebrosidase (GBA) protein and/or activity are potential new treatments for Parkinson’s disease. This project will use flow cytometry to develop and t...
Visit PagePeople with certain genetic differences (mutations) in the LRRK2 gene are at much greater risk of getting Parkinson’s. While only a small percentage of all Parkinson’s cases are directly due to LRRK2 mutations understanding what LRRK2 does and what it may do differently in Parkinson’s disease ...
Visit PageShake It Up Australia Foundation is delighted to be funding more world leading research at Neuroscience Research Australia (NeuRA). The twelve month research grant funded in partnership with The Michael J. Fox Foundation for Parkinson’s Research will enable Professor Glenda Halliday and Dr Nicolas...
Visit PageShake It Up Australia Foundation is delighted to announce new funding for world’s best research being conducted at Neuroscience Research Australia (NeuRA). The twelve month research grant funded in partnership with The Michael J. Fox Foundation for Parkinson’s Research will enable Professor Glen...
Visit PageSince establishment in 2011 Shake It Up has committed over $1M to Parkinson’s research in Australia. Through our partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) we know that this research is world’s best and strategically important in the quest for better treatme...
Visit PageThis week, Michael J. Fox Foundation CEO Todd Sherer, PhD, is attending the 17th Annual Movement Disorder Society Congress in Sydney, Australia, one of the largest international gatherings of experts in Parkinson’s disease (PD) and other movement disorders. Sherer also took advantage of his tr...
Visit PageTwo genes related to protein accumulation in the brains of people with Parkinson’s disease can indicate how quickly the disease will progress in an individual, say NeuRA researchers. “Our study shows that these two genes can be used as a surrogate marker to estimate the rate of Parkinson’s dis...
Visit PageShake It Up Australia and The Michael J. Fox Foundation (MJFF) today announced the first of up to $3 million worth of Australian research grants to help find a cure for Parkinson’s disease. The research will explore the potential link between the immune system and the gene LRRK2 in people with...
Visit PageThis grant will allow us to determine whether LRRK2 affects innate immunity, the first non-specific line of immune defence, and whether LRRK2 function in immune cells is changed in patients with Parkinson’s disease,” Prof. Halliday said
Visit Page